Five things for pharma marketers to know: Monday, July 25, 2016

1. Researchers said the newly approved multiple myeloma drug Darzalex, which is manufactured by Johnson & Johnson, may interfere with blood testing prior to transfusions. They added that this may raise questions about other monoclonal antibodies. (MedPage Today)

2. Virginia governor Tim Kaine, who was selected as Hillary Clinton's running mate last week, is under scrutiny by Republicans for his ties to the drug industry — including Barr Pharmaceuticals, now owned by Teva. (NYT)

3. About 100 national and state medical societies said they support a Senate bill exempting drug and medical device makers from reporting CME payments they make to doctors. The requirement stems from the Physician Payment Sunshine Act. (Stat)

4. A malaria drug, atovaquone, may make cancer cells more susceptible to radiotherapy and is now being tested in a clinical trial. GlaxoSmithKline sells a branded version of the drug, combined with proguanil, called Malarone. (Reuters)

5. The development of drugs to treat rare diseases is likely to benefit from increased engagement and input from patients, a study found. (Nature)